Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

11352results about "SsDNA viruses" patented technology

Composition for regulating production of interfering ribonucleic acid

Embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause a decrease in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a dopamine receptor. In some embodiments of the present disclosure, the target biomolecule is a dopamine receptor such as the D1 dopamine receptor, such as the D2 dopamine receptor, such as the D3 dopamine receptor, or such as the D4 dopamine receptor.
Owner:WYVERN PHARMACEUTICALS INC

Composition for regulating production of interfering ribonucleic acid

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.
Owner:WYVERN PHARMACEUTICALS INC

Composition for regulating production of interfering ribonucleic acid

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as JAK. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.
Owner:WYVERN PHARMACEUTICALS INC

AAV-IDS vectors for treatment of mucopolysaccharidosis ii

ActiveUS20240366789A1VectorsMetabolism disorderIduronate SulfataseHuman cell
This invention relates to viral vectors for delivery of iduronate-2-sulfatase (IDS) to a subject. In some aspects the IDS sequence is optimized for expression in human cells. The invention further relates to methods of using the vector to increase secretion of IDS from a cell and for treatment and prevention of mucopolysaccharidosis II.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Compositions and methods for treating neurocognitive disorders

To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A
Owner:AVROBIO INC

Alternative splicing regulation of gene expression and therapeutic methods

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA

Intein proteins and uses thereof

PendingJP2025020111ASenses disorderSplicing alterationInteinProtein reconstitution
To provide constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.SOLUTION: The present invention implements cellular large protein reconstitution by providing to a target cell two or more fragments of large protein fused to split inteins to promote intein-mediated trans-splicing and reconstitute the functional protein.SELECTED DRAWING: None
Owner:FOND AZIONE TELETHON

Engineered blood brain barrier penetrant AAV capsids

PCT designated stage expiredWO2024238684A1Nervous disorderVectorsMedicineBlood brain barrier penetration
This application relates to engineering AAV capsids. In some embodiments, the engineered AAV capsids are capable of penetrating the blood brain barrier and transducing cells in the central nervous system.
Owner:SANGAMO THERAPEUTICS INC

Composition for regulating production of interfering ribonucleic acid

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as ETS2. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to overexpression of the target biomolecule.
Owner:WYVERN PHARMACEUTICALS INC

Fitness maturation of engineered AAV capsid STAC-102

This application relates to engineering AAV capsids, for example, STAC-102. In some embodiments, the engineered AAV capsids mediate delivery to the central nervous system.
Owner:SANGAMO THERAPEUTICS INC

Compositions and methods for regulating mapt

The disclosure relates to small interfering RNA (siRNA) molecules targeting MAPT and adeno-associated viral (AAV) particles encoding the same for treating tauopathies.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency

PCT designated stage expiredWO2024229167A1Organic active ingredientsNervous disorderSTXBP1Capsid
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of STXBP1 proteins via delivery using an adeno-associated virus (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having STXBP1 encephalopathy, or another STXBP1-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to CDKL5 deficiency

PCT designated stage expiredWO2024229163A1Nervous disorderPeptide/protein ingredientsCDKL5Capsid
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of CDKL5 proteins via delivery using an adeno-associated virus (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having CDD, or another CDKL5-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Gene editing pairs

PendingUS20250043262A1HydrolasesStable introduction of DNAEngineering proteinWild type
Provided herein are gene editing pairs comprising an engineered protein, e.g, an engineered CRISPR protein and a guide ribonucleic acid (gRNA) that may provide improved gene editing relative to reference, i.e., wild type sequences. In some embodiments, the engineered protein of the gene editing pair comprises a RuvC cleavage domain with one or more amino acid modifications relative to a reference CRISPR protein RuvC sequence. In some embodiments, a guide ribonucleic acid (gRNA) of the gene editing pair comprises at least one modification in a scaffold stem loop relative to a reference scaffold stem loop sequence.
Owner:SCRIBE THERAPEUTICS INC

TnpB-omega RNA gene editing system and application

The invention provides a modified TnpB-omega RNA gene editing system and application of the modified TnpB-omega RNA gene editing system. In particular, the present invention provides a modified TnpB related [omega] RNA skeleton. The modified omega RNA skeleton provided by the invention has at least three stem-loop structure fragments, and has a shorter length and a compact structure than a natural omega RNA skeleton, so that the modified omega RNA skeleton and TnpB can be jointly carried in a single AAV vector, the administration efficiency is improved, and high-efficiency gene editing is realized.
Owner:LINGANG LAB

Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency

PCT designated stage expiredWO2024229161A1Polypeptide with localisation/targeting motifNervous disorderAdenoassociated virusGlucosylceramidase beta
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Owner:VOYAGER THERAPEUTICS INC

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

ActiveUS12274733B2Senses disorderNervous disorderTissue repairVaccine virus
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Compositions and methods for the treatment of disorders related to ataxin-2

The disclosure relates to compositions and methods for modulating, e.g., reducing or eliminating, the expression of ATXN2 via delivery of a modulatory polynucleotide using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having, spinocerebellar ataxia type 2 or another ATXN2-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to frataxin deficiency

PCT designated stage expiredWO2024229125A2Organic active ingredientsVectorsFriedreichs ataxiaFrataxin
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of frataxin protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or suspected of having a disorder associated with frataxin (FXN) deficiency, e.g., Friedreich's Ataxia.
Owner:VOYAGER THERAPEUTICS INC